Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-039898
Filing Date
2023-08-08
Accepted
2023-08-08 16:33:51
Documents
59
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20230630.htm   iXBRL 10-Q 3240770
2 EX-31.1 janx-ex31_1.htm EX-31.1 22130
3 EX-31.2 janx-ex31_2.htm EX-31.2 20789
4 EX-32.1 janx-ex32_1.htm EX-32.1 18856
  Complete submission text file 0000950170-23-039898.txt   12631872

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT janx-20230630_def.xml EX-101.DEF 199462
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230630.xsd EX-101.SCH 48537
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230630_pre.xml EX-101.PRE 306137
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230630_lab.xml EX-101.LAB 424201
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT janx-20230630_cal.xml EX-101.CAL 46078
53 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230630_htm.xml XML 3246041
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 231151985
SIC: 2834 Pharmaceutical Preparations